DD222495A5 - Verfahren zur herstellung einer zweiphasigen festen arzneizubereitung - Google Patents

Verfahren zur herstellung einer zweiphasigen festen arzneizubereitung Download PDF

Info

Publication number: DD222495A5
Authority: DD; German Democratic Republic
Prior art keywords: nifedipine; crystalline; granules; preparation; coprecipitate
Prior art date: 1983-05-21

Application number

DD84263172A

Other languages

German (de)

English (en)

Inventor

Ahmed Hegasy

Roland Rupp

Klaus-Dieter Raemsch

Helmut Luchtenberg

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-05-21

Filing date

1984-05-18

Publication date

1985-05-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6199643&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DD222495(A5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1984-05-18 Application filed by Bayer Ag filed Critical Bayer Ag

1985-05-22 Publication of DD222495A5 publication Critical patent/DD222495A5/de

Links

239000007787 solid Substances 0.000 title claims abstract description 15
238000002360 preparation method Methods 0.000 title claims description 16
238000004519 manufacturing process Methods 0.000 title abstract description 5
229940079593 drug Drugs 0.000 title description 5
239000003814 drug Substances 0.000 title description 5
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims abstract description 40
229960001597 nifedipine Drugs 0.000 claims abstract description 40
239000000203 mixture Substances 0.000 claims abstract description 17
238000000034 method Methods 0.000 claims abstract description 12
239000002904 solvent Substances 0.000 claims abstract description 9
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 7
239000002245 particle Substances 0.000 claims abstract description 6
239000003960 organic solvent Substances 0.000 claims abstract description 5
238000005469 granulation Methods 0.000 claims abstract 2
230000003179 granulation Effects 0.000 claims abstract 2
229940124531 pharmaceutical excipient Drugs 0.000 claims abstract 2
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 24
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 24
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 23
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 20
-1 aliphatic alcohols Chemical class 0.000 claims description 4
229920002678 cellulose Polymers 0.000 claims description 3
229920002472 Starch Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
235000019698 starch Nutrition 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
239000003937 drug carrier Substances 0.000 claims 1
239000002244 precipitate Substances 0.000 claims 1
239000008187 granular material Substances 0.000 description 31
229920002261 Corn starch Polymers 0.000 description 18
239000008120 corn starch Substances 0.000 description 18
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
229920000168 Microcrystalline cellulose Polymers 0.000 description 11
235000019813 microcrystalline cellulose Nutrition 0.000 description 11
239000008108 microcrystalline cellulose Substances 0.000 description 11
229940016286 microcrystalline cellulose Drugs 0.000 description 11
235000019359 magnesium stearate Nutrition 0.000 description 9
238000009472 formulation Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
239000002775 capsule Substances 0.000 description 6
235000019441 ethanol Nutrition 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
239000008298 dragée Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000011282 treatment Methods 0.000 description 4
239000001828 Gelatine Substances 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000001035 drying Methods 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
208000029078 coronary artery disease Diseases 0.000 description 2
239000013078 crystal Substances 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
230000001077 hypotensive effect Effects 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
239000000463 material Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000000454 talc Substances 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
206010034972 Photosensitivity reaction Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000003276 anti-hypertensive effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
125000005228 aryl sulfonate group Chemical group 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
230000037058 blood plasma level Effects 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
238000012153 long-term therapy Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
238000002156 mixing Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000036211 photosensitivity Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000011435 rock Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000006104 solid solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001694 spray drying Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pyridine Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Detergent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Cosmetics (AREA)
Materials For Medical Uses (AREA)
Compounds Of Unknown Constitution (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DD84263172A 1983-05-21 1984-05-18 Verfahren zur herstellung einer zweiphasigen festen arzneizubereitung DD222495A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19833318649 DE3318649A1 (de)	1983-05-21	1983-05-21	Zweiphasenformulierung

Publications (1)

Publication Number	Publication Date
DD222495A5 true DD222495A5 (de)	1985-05-22

Family

ID=6199643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD84263172A DD222495A5 (de)	1983-05-21	1984-05-18	Verfahren zur herstellung einer zweiphasigen festen arzneizubereitung

Country Status (29)

Country	Link
US (1)	US4562069A (da)
EP (1)	EP0126379B1 (da)
JP (1)	JPS59222475A (da)
AT (2)	ATE42198T1 (da)
AU (1)	AU564263B2 (da)
BE (1)	BE899691A (da)
CA (1)	CA1228550A (da)
CH (1)	CH658190A5 (da)
CS (1)	CS250663B2 (da)
DD (1)	DD222495A5 (da)
DE (2)	DE3318649A1 (da)
DK (1)	DK163278C (da)
ES (1)	ES8505817A1 (da)
FI (1)	FI82376C (da)
FR (1)	FR2550092B1 (da)
GB (1)	GB2139892B (da)
GR (1)	GR82018B (da)
HK (1)	HK63789A (da)
HU (1)	HU193287B (da)
IL (1)	IL71871A (da)
IT (1)	IT1218848B (da)
KE (1)	KE3889A (da)
NO (1)	NO164817C (da)
NZ (1)	NZ208214A (da)
PH (1)	PH21989A (da)
PL (1)	PL142890B1 (da)
PT (1)	PT78611B (da)
SG (1)	SG36089G (da)
ZA (1)	ZA843769B (da)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2525108B1 (fr) *	1982-04-19	1989-05-12	Elan Corp Ltd	Medicaments a haut degre de solubilite et procede pour leur obtention
DE3580384D1 (de) *	1984-04-09	1990-12-13	Toyo Boseki	Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
NL194389C (nl) *	1984-06-14	2002-03-04	Novartis Ag	Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
DE3424553A1 (de) *	1984-07-04	1986-01-09	Bayer Ag, 5090 Leverkusen	Feste arzneizubereitungen mit dihydropyridinen und verfahren zu ihrer herstellung
DE3438830A1 (de) *	1984-10-23	1986-04-30	Rentschler Arzneimittel	Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
US4867984A (en) *	1984-11-06	1989-09-19	Nagin K. Patel	Drug in bead form and process for preparing same
IT1187751B (it) *	1985-10-15	1987-12-23	Eurand Spa	Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
US5198226A (en) *	1986-01-30	1993-03-30	Syntex (U.S.A.) Inc.	Long acting nicardipine hydrochloride formulation
US4940556A (en) *	1986-01-30	1990-07-10	Syntex (U.S.A.) Inc.	Method of preparing long acting formulation
IE63321B1 (en) *	1986-02-03	1995-04-05	Elan Corp Plc	Drug delivery system
SE8601624D0 (sv) *	1986-04-11	1986-04-11	Haessle Ab	New pharmaceutical preparations
DE3636123A1 (de) *	1986-10-23	1988-05-05	Rentschler Arzneimittel	Arzneizubereitungen zur oralen verabreichung, die als einzeldosis 10 bis 240 mg dihydropyridin enthalten
DE3639073A1 (de) *	1986-11-14	1988-05-26	Klinge Co Chem Pharm Fab	Feste arzneizubereitungen und verfahren zu ihrer herstellung
US5015479A (en) *	1987-02-02	1991-05-14	Seamus Mulligan	Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
DE3720757A1 (de) *	1987-06-24	1989-01-05	Bayer Ag	Dhp-manteltablette
US4954346A (en) *	1988-06-08	1990-09-04	Ciba-Geigy Corporation	Orally administrable nifedipine solution in a solid light resistant dosage form
GB8903328D0 (en) *	1989-02-14	1989-04-05	Ethical Pharma Ltd	Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
HU203041B (en) *	1989-03-14	1991-05-28	Egyt Gyogyszervegyeszeti Gyar	Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
GB9025251D0 (en) *	1990-11-20	1991-01-02	Solomon Montague C	Nifedipine dosage forms
DE4130173A1 (de) *	1991-09-11	1993-03-18	Bayer Ag	Pharmazeutische zubereitungen mit einer speziellen kristallmodifikation des 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridindicarbonsaeure-isopropyl-(2-methoxyethyl)-esters
US5662933A (en) *	1993-09-09	1997-09-02	Edward Mendell Co., Inc.	Controlled release formulation (albuterol)
US6726930B1 (en) *	1993-09-09	2004-04-27	Penwest Pharmaceuticals Co.	Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) *	1993-09-09	1995-10-03	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) *	1993-09-09	1998-06-30	Edward Mendell Co., Inc.	Sustained release heterodisperse hydrogel systems--amorphous drugs
US5543099A (en) *	1994-09-29	1996-08-06	Hallmark Pharmaceutical, Inc.	Process to manufacture micronized nifedipine granules for sustained release medicaments
IL123505A (en)	1996-07-08	2004-12-15	Penwest Pharmaceuticals Compan	Sustained release matrix for high-dose insoluble drugs
EP0852141A1 (en) *	1996-08-16	1998-07-08	J.B. Chemicals & Pharmaceuticals Ltd.	Nifedipine containing pharmaceutical extended release composition and a process for the preparation thereof
US5891469A (en) *	1997-04-02	1999-04-06	Pharmos Corporation	Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5837379A (en) *	1997-01-31	1998-11-17	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
US5922352A (en) *	1997-01-31	1999-07-13	Andrx Pharmaceuticals, Inc.	Once daily calcium channel blocker tablet having a delayed release core
IN186245B (da)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US6056977A (en)	1997-10-15	2000-05-02	Edward Mendell Co., Inc.	Once-a-day controlled release sulfonylurea formulation
US6485748B1 (en)	1997-12-12	2002-11-26	Andrx Pharmaceuticals, Inc.	Once daily pharmaceutical tablet having a unitary core
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
WO2000018374A1 (en) *	1998-10-01	2000-04-06	Elan Pharma International, Ltd.	Controlled release nanoparticulate compositions
US20040013613A1 (en) *	2001-05-18	2004-01-22	Jain Rajeev A	Rapidly disintegrating solid oral dosage form
US8236352B2 (en)	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US7521068B2 (en) *	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US6969529B2 (en) *	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6168806B1 (en)	1999-03-05	2001-01-02	Fang-Yu Lee	Orally administrable nifedipine pellet and process for the preparation thereof
ES2304980T3 (es) *	1999-09-30	2008-11-01	Penwest Pharmaceuticals Co.	Sistemas de matriz de liberacion sostenida para farmacos altamente solubles.
US20040156872A1 (en) *	2000-05-18	2004-08-12	Elan Pharma International Ltd.	Novel nimesulide compositions
US7198795B2 (en)	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US7276249B2 (en)	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
WO2003033462A2 (en) *	2001-10-15	2003-04-24	The Regents Of The University Of Michigan	Systems and methods for the generation of crystalline polymorphs
CA2475092C (en)	2002-02-04	2012-05-01	Baudax Bio, Inc.	Nanoparticulate compositions having lysozyme as a surface stabilizer
WO2004006959A1 (en) *	2002-07-16	2004-01-22	Elan Pharma International, Ltd	Liquid dosage compositions of stable nanoparticulate active agents
CN101702878B (zh) *	2007-05-11	2012-11-28	弗·哈夫曼-拉罗切有限公司	可溶性差的药物的药物组合物
US20150011525A1 (en) *	2011-09-13	2015-01-08	Isp Investments Inc.	Solid dispersion of poorly soluble compounds comprising crospovidone and at least one water-soluble polymer
US20130259931A1 (en) *	2012-03-30	2013-10-03	Bandi Parthasaradhi Reddy	Oral pharmaceutical compositions of nebivolol and process for their preparation
US8313774B1 (en) *	2012-06-26	2012-11-20	Magnifica Inc.	Oral solid composition

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1579818A (en) *	1977-06-07	1980-11-26	Yamanouchi Pharma Co Ltd	Nifedipine-containing solid preparation composition
JPS5446837A (en) *	1977-09-19	1979-04-13	Kanebo Ltd	Easily absorbable nifedipin composition, its preparation, and anti-stenocardia containing the same
EP0001247A1 (en) *	1977-09-14	1979-04-04	Kanebo, Ltd.	Pharmaceutical preparation containing nifedipine and a method for producing the same.
EP0012523B2 (en) *	1978-11-20	1988-02-03	American Home Products Corporation	Therapeutic compositions with enhanced bioavailability and process for their preparation
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) *	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
JPS56110612A (en) *	1980-02-08	1981-09-01	Yamanouchi Pharmaceut Co Ltd	Readily disintegrable and absorbable compression molded article of slightly soluble drug
DE3033919A1 (de) *	1980-09-09	1982-04-22	Bayer Ag, 5090 Leverkusen	Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5668619A (en) *	1980-10-09	1981-06-09	Yamanouchi Pharmaceut Co Ltd	Nifedipine-containing solid composition
JPS5785316A (en) *	1980-11-14	1982-05-28	Kanebo Ltd	Preparation of easily absorbable nifedipine preparation
JPS57167911A (en) *	1981-04-09	1982-10-16	Kyoto Yakuhin Kogyo Kk	Liquid pharmaceutical of nifedipine
JPS5846019A (ja) *	1981-09-14	1983-03-17	Kanebo Ltd	持続性ニフエジピン製剤
DE3142853A1 (de) *	1981-10-29	1983-05-11	Bayer Ag, 5090 Leverkusen	Feste arzneizubereitungen mit nifedipin und verfahren zu ihrer herstellung
DE3270785D1 (en) *	1981-10-29	1986-05-28	Bayer Ag	Process for preparing solid fast-releasing drug formulations of dihydropyridines
JPS5877811A (ja) *	1981-11-04	1983-05-11	Kanebo Ltd	安定な易吸収性ニフエジピン製剤の製法

1983
- 1983-05-21 DE DE19833318649 patent/DE3318649A1/de not_active Withdrawn
1984
- 1984-05-02 US US06/606,104 patent/US4562069A/en not_active Expired - Lifetime
- 1984-05-08 NO NO841838A patent/NO164817C/no unknown
- 1984-05-09 EP EP84105235A patent/EP0126379B1/de not_active Expired
- 1984-05-09 AT AT84105235T patent/ATE42198T1/de not_active IP Right Cessation
- 1984-05-09 DE DE8484105235T patent/DE3477733D1/de not_active Expired
- 1984-05-16 ES ES532515A patent/ES8505817A1/es not_active Expired
- 1984-05-16 AU AU28060/84A patent/AU564263B2/en not_active Ceased
- 1984-05-17 BE BE0/212957A patent/BE899691A/fr not_active IP Right Cessation
- 1984-05-17 DK DK247284A patent/DK163278C/da active
- 1984-05-17 JP JP59097625A patent/JPS59222475A/ja active Pending
- 1984-05-17 FI FI841995A patent/FI82376C/fi not_active IP Right Cessation
- 1984-05-18 PH PH30694A patent/PH21989A/en unknown
- 1984-05-18 HU HU841934A patent/HU193287B/hu not_active IP Right Cessation
- 1984-05-18 FR FR8407731A patent/FR2550092B1/fr not_active Expired
- 1984-05-18 IT IT21013/84A patent/IT1218848B/it active
- 1984-05-18 CS CS843770A patent/CS250663B2/cs unknown
- 1984-05-18 PT PT78611A patent/PT78611B/pt not_active IP Right Cessation
- 1984-05-18 PL PL1984247744A patent/PL142890B1/pl unknown
- 1984-05-18 CH CH2465/84A patent/CH658190A5/de not_active IP Right Cessation
- 1984-05-18 AT AT0164884A patent/AT390879B/de active
- 1984-05-18 CA CA000454635A patent/CA1228550A/en not_active Expired
- 1984-05-18 ZA ZA843769A patent/ZA843769B/xx unknown
- 1984-05-18 DD DD84263172A patent/DD222495A5/de not_active IP Right Cessation
- 1984-05-18 NZ NZ208214A patent/NZ208214A/xx unknown
- 1984-05-18 IL IL71871A patent/IL71871A/xx unknown
- 1984-05-18 GB GB08412820A patent/GB2139892B/en not_active Expired
- 1984-05-21 GR GR74767A patent/GR82018B/el unknown
1989
- 1989-06-07 SG SG360/89A patent/SG36089G/en unknown
- 1989-06-21 KE KE3889A patent/KE3889A/xx unknown
- 1989-08-10 HK HK637/89A patent/HK63789A/xx unknown

Also Published As

Publication number	Publication date
NO164817B (no)	1990-08-13
DK247284D0 (da)	1984-05-17
GR82018B (da)	1984-12-12
CS250663B2 (en)	1987-05-14
HK63789A (en)	1989-08-18
ATA164884A (de)	1990-01-15
FI841995A0 (fi)	1984-05-17
KE3889A (en)	1989-09-01
IL71871A0 (en)	1984-09-30
DK163278B (da)	1992-02-17
AU564263B2 (en)	1987-08-06
ES532515A0 (es)	1985-06-16
AT390879B (de)	1990-07-10
EP0126379B1 (de)	1989-04-19
FI82376C (fi)	1991-03-11
DE3318649A1 (de)	1984-11-22
PH21989A (en)	1988-05-02
DK247284A (da)	1984-11-22
NO841838L (no)	1984-11-22
PT78611A (en)	1984-06-01
PT78611B (en)	1986-07-15
DE3477733D1 (en)	1989-05-24
US4562069A (en)	1985-12-31
GB8412820D0 (en)	1984-06-27
GB2139892A (en)	1984-11-21
AU2806084A (en)	1984-11-22
FI841995L (fi)	1984-11-22
PL247744A1 (en)	1985-11-05
HUT34690A (en)	1985-04-28
NO164817C (no)	1990-12-19
EP0126379A3 (en)	1986-07-09
IL71871A (en)	1987-07-31
SG36089G (en)	1989-10-13
IT8421013A0 (it)	1984-05-18
BE899691A (fr)	1984-11-19
FI82376B (fi)	1990-11-30
ES8505817A1 (es)	1985-06-16
FR2550092A1 (fr)	1985-02-08
PL142890B1 (en)	1987-12-31
GB2139892B (en)	1987-04-23
ATE42198T1 (de)	1989-05-15
DK163278C (da)	1992-09-07
JPS59222475A (ja)	1984-12-14
CA1228550A (en)	1987-10-27
HU193287B (en)	1987-09-28
NZ208214A (en)	1986-10-08
CH658190A5 (de)	1986-10-31
IT1218848B (it)	1990-04-24
EP0126379A2 (de)	1984-11-28
ZA843769B (en)	1984-12-24
FR2550092B1 (fr)	1987-11-20

Legal Events

Date	Code	Title	Description
1994-08-18	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0126379B1 (de)	1989-04-19	Zweiphasenformulierung
EP0078430B1 (de)	1986-04-23	Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
EP0108898B1 (de)	1986-08-20	Neue orale Mopidamolformen
EP0128482B1 (de)	1990-01-31	Neue galenische Zubereitungsformen von oralen Antidiabetika und Verfahren zu ihrer Herstellung
EP0047899B2 (de)	1996-02-28	Feste Arzneizubereitungen enthaltend Nifedipin und Verfahren zu ihrer Herstellung
DE69936352T2 (de)	2008-02-14	Stabilisierung von rapamycinen oder rapamycinderivaten
EP0265848B1 (de)	1991-09-25	Arzneizubereitungen zur oralen Verabreichung, die als Einzeldosis 10 bis 240 mg Dihydropyridin enthalten
DE2845326C2 (de)	1985-05-23	Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE69511539T2 (de)	2000-03-30	Eine cyclosporin enthaltende zubereitung und ein verfahren für ihre herstellung
DE69110592T2 (de)	1995-12-21	Pharmazeutische Zubereitung mit verbessertem Geschmack, poröse Partikel enthaltend, und deren Herstellungsmethode.
CH659467A5 (de)	1987-01-30	Verfahren zur herstellung von nifedipin-trockenpraeparaten.
DE2822882A1 (de)	1978-12-21	Nifedipine-enthaltende feste praeparatzusammensetzung, verfahren zu ihrer herstellung und ihre verwendung
DD263231A5 (de)	1988-12-28	Verfahren zur herstellung eines festen praeparates mit verzoegerter abgabe eines wirkstoffes
DE3500103A1 (de)	1986-07-10	Pharmazeutische zubereitung mit einem in wasser und verdauungssaeften schwer loeslichen wirkstoff
DE3720757A1 (de)	1989-01-05	Dhp-manteltablette
WO2008064854A1 (de)	2008-06-05	Arzneimittelzubereitung von tramadol und acetaminophen
DE69814850T2 (de)	2004-03-11	Paracetamol enthaltende schlickbare tablette
DE3142853C2 (da)	1989-06-29
DE60103276T2 (de)	2005-06-23	Eine stabile pharmazeutische formulierung die torsemid modifikation ii enthält
DE3586472T2 (de)	1993-02-11	Nichtstaubende antibiotische vormischungszusammensetzungen gegen coccidiose und verfahren zu deren herstellung.
DE69807745T2 (de)	2003-05-15	Monoargininylsalz der (e)-3-[1-n-butyl-5-[(2-(2-carboxyphenyl)methoxy-4-chlorphenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-en carbonsäure
DD235183A5 (de)	1986-04-30	Verfahren zur herstellung von dihydropyridinpraeparaten
DE3419131A1 (de)	1985-11-28	Dihydropyridinkombinationspraeparate und verfahren zu ihrer herstellung
DE2614864C3 (de)	1979-11-29	Verfahren zur Herstellung Digoxin enthaltender Arzneipräparate in Weichgelatinekapseln zur oralen Verabfolgung
DE3736691C2 (da)	1991-05-23